药石科技 (300725)
PharmaBlock Sciences (Nanjing), Inc.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 23380.73
- Circulating A-Shares(W): 20271.39
- Earnings Per Share(RMB): 0.5635
- Net Assets Per Share(RMB): 30.5765
- Operating Revenue(W RMB): 141905.49
- Total Profit(W RMB): 12823.42
- Net Profit Attributable to Parent(W RMB): 11339.06
- Net Profit Growth Rate(%): -13.96
- Weighted Return on Equity(%): 2.4800
- Operating Cash Flow Per Share(RMB): 2.3250
- Undistributed Profit Per Share(RMB): 6.6488
- Capital Reserve Per Share(RMB): 10.0339
2. Main Business
The main business covers:
- Innovative chemical products and services in the global pharmaceutical R&D and manufacturing field.
3. Company Basic Information
- Company Name: PharmaBlock Sciences (Nanjing), Inc.
- Listing Date: 2017-11-10
- Industry: Research and Experimental Development
- Address: No. 81 Huasheng Road, Jiangbei New District, Nanjing, Jiangsu Province
- Website: www.pharmablock.com
- Company Profile：On November 20, 2006, Hong Kong PharmaBlock held a board meeting and passed a resolution to establish PharmaBlock Limited. The registered capital of PharmaBlock Limited at its establishment was USD 5 million, fully subscribed by Hong Kong PharmaBlock. On December 18, 2006, the Nanjing Municipal People's Government issued the approval document Ning Fu Wai Jing Mao Zi Shen [2006] No. 15043 "Approval on the Establishment of Nanjing PharmaBlock Pharmaceutical R&D Co., Ltd.", approving the establishment of PharmaBlock Limited. On December 21, 2006, the Nanjing Municipal People's Government issued the Approval Certificate for Enterprises with Investment from Hong Kong, Macao, Taiwan and Overseas Chinese, No. Shang Wai Zi Ning Fu Du Zi Zi [2006] 4290. On December 26, 2006, PharmaBlock Limited completed its establishment and obtained the Business License with registration number Qi Du Su Ning Zong Zi No. 008431 issued by the Nanjing Administration for Industry and Commerce. According to the resolution passed at the founding meeting held by the original shareholders of PharmaBlock Limited as promoters on December 1, 2015, based on the net assets of RMB 143,004,384.40 as of October 31, 2015 audited by Tianheng Certified Public Accountants (Special General Partnership), and converted at a ratio of 2.86008769:1 into a share capital of RMB 50 million, PharmaBlock Limited was transformed into a joint stock company. On December 1, 2015, Tianheng Certified Public Accountants (Special General Partnership) issued the Capital Verification Report Tian Heng Yan Zi (2015) 02145, verifying that the capital contributions of all promoters had been fully paid as of October 31, 2015. On December 16, 2015, the company completed the industrial and commercial change registration with the High-tech Industrial Development Zone Branch of the Nanjing Administration for Industry and Commerce and obtained the Business License with Unified Social Credit Code 913201917937313394.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Henan Hengtong Boyuan Venture Capital Partnership (Limited Partnership) | General Legal Person | 392.96 | 1.94 |
| 2 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 174.19 | 0.86 |
| 3 | Southern China Securities 1000 ETF | Fund | 170.54 | 0.84 |
| 4 | Penghua Pharmaceutical Technology Equity Securities Investment Fund Class A | Fund | 138.09 | 0.68 |
| 5 | Morgan Stanley Youyue Anhe Hybrid Securities Investment Fund Class A | Fund | 6.44 | 0.03 |
| 6 | Jinyuan Shun'an Xinyi Hybrid Initiated Securities Investment Fund Class A | Fund | 1.03 | 0.01 |
5. Concept Sectors
- Artificial Intelligence
- CXO Concept
- Innovative Drugs
- Synthetic Biology
- AI in Healthcare
- Margin Trading & Securities Lending
- High-Performance Stocks
- Overseas Business
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information